P-152 - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: analysis of Glasgow prognostic score (GPS)

Abstract

Abstract Background It is important to predict prognosis in patients with advanced gastric cancer receiving chemotherapy. Several studies have reported that Glasgow prognostic score (GPS), which was based on serum albumin (Alb) and C-reactive protein (CRP), was associated with poor prognosis in many cancers. However, it is unclear whether GPS has prognostic value when patients receive Irinotecan, which is a key drug of advanced gastric cancer. Methods We conducted a retrospective multicenter study and investigated association between efficacy and GPS in patients who received irinotecan monotherapy between January 2010 and December 2017. All patients had to receive fluoropyrimidine and platinum as prior therapy. GPS was identified that GPS 0 was CRP ≤1.0 mg/dL and Alb ≥3.5 g/dL, GPS 1 was CRP >1.0 mg/dL or Alb 1.0 mg/dL and Alb Results There were 174 patients at 8 centers included in this study. The number of patients with GPS 0/1/2 was 76/56/42, respectively. In GPS 0/1/2 patients, performance status (0-1/2≤), treatment line 2nd/3rd or later, and HER2 status were significantly different among them(p Conclusions In this analysis, GPS might be a predictive and prognostic factor in treatment with irinotecan monotherapy for patients with AGC. Legal entity responsible for the study Yoshito Komatsu. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.